JPMorgan Chase & Co. Reiterates “Neutral” Rating for Smith & Nephew (SN)
Smith & Nephew (LON:SN)‘s stock had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Monday, ARN reports.
Smith & Nephew (LON:SN) traded up 1.26% on Monday, hitting GBX 887.00. The stock had a trading volume of 3,515,072 shares. Smith & Nephew has a 1-year low of GBX 692.592 and a 1-year high of GBX 897.00. The stock’s 50-day moving average is GBX 868.9 and its 200-day moving average is GBX 810.2. The company’s market cap is £7.974 billion.
A number of other firms have also recently commented on SN. Analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew in a research note to investors on Wednesday, January 29th. They now have a GBX 920 ($15.12) price target on the stock. Separately, analysts at UBS AG upgraded shares of Smith & Nephew to a “buy” rating in a research note to investors on Monday, January 27th. They now have a GBX 1,000 ($16.43) price target on the stock, up previously from GBX 780 ($12.82). Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of Smith & Nephew in a research note to investors on Thursday, January 23rd. They now have a GBX 650 ($10.68) price target on the stock. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 837.25 ($13.76).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.